General MedicationsORALStandard
REYATAZ
ATAZANAVIR SULFATE
Standard Dose
EQ 50MG BASE/PACKET
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview REYATAZ is listed in Drugs@FDA under application 206352 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient ATAZANAVIR SULFATE Form and strength POWDER;ORAL - EQ 50MG BASE/PACKET Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2024-12-05 00:00:00.
Structured Monograph
Clinical summary
Approval overview REYATAZ is listed in Drugs@FDA under application 206352 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ATAZANAVIR SULFATE Form and strength POWDER;ORAL - EQ 50MG BASE/PACKET Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2024-12-05 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.